Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX with or without cetuximab: NCCTG N0147.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Frank A. Sinicrope, Michelle R. Mahoney, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Garth D. Nelson, Daniel J. Sargent, Steven R. Alberts, North Central Cancer Treatment Group
Institution: Mayo Clinic
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2230954359